{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:01:18Z","timestamp":1786672878410,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Boehringer Ingelheim"},{"name":"boehringer ingelheim"},{"name":"Boehringer Ingelheim International GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the change in visual acuity (VA) in participants with intermediate age-related macular degeneration (iAMD) over two years when categorised by the presence or absence of incomplete retinal and retinal pigment atrophy (iRORA) and subretinal drusenoid deposits (SDD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/Methods<\/jats:title>\n                    <jats:p>In this multicentre cohort study, participants with iAMD were classified as: i) iAMD with no iRORA or SDD; ii) iAMD with SDD with no iRORA; iii) iAMD with iRORA with no SDD and iv) iAMD with iRORA and SDD. The change in best recorded visual acuity (BRVA) over two years in the whole cohort and in each sub-category was analysed using linear mixed effect models employing an unstructured covariance structure. Associations with age, sex and baseline BRVA were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      983 eyes from 805 participants were analysed. The mean baseline VA changed from 79.8 (SD 8.1) to 77.7 (SD 10.1) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score at two years, with a mean unadjusted change in BRVA of \u22120.33 ETDRS letters (95% CI \u22120.72,0.06);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.10 at 6 months, \u22120.65 ETDRS letters (95% CI \u22121.14, \u22120.16);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01 at 12 months, \u22121.45 ETDRS letters (95% CI \u22122.03, \u22120.86);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001 at 18 months and \u22122.16 ETDRS letters (95% CI \u22122.79, \u22121.53);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001 at 24 months. All sub-categories showed a small decline in BRVA. Increasing age and lower baseline visual acuity were associated with lower BRVA over two years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Eyes with iAMD experience a small mean decline of ~2 letters over two years. Overall, these changes may not represent a clinically meaningful difference.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04062-z","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:26:59Z","timestamp":1760722019000},"page":"3324-3332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baseline factors that are associated with change in visual acuity in intermediate AMD over two years in a multicentre cohort study in Europe- INTERCEPT-AMD Report 2"],"prefix":"10.1038","volume":"39","author":[{"given":"Sarega","family":"Gurudas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Girmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Lechanteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Parravano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieselotte","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansj\u00fcrgen","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Barr\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Tsiroukis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Mon\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sararols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-0833","authenticated-orcid":false,"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik P. N.","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-1539","authenticated-orcid":false,"given":"Boris","family":"Stanzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-9967","authenticated-orcid":false,"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the INTERCEPT-AMD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Liermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Madhusudhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyubomyr","family":"Lytvynchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Eter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"de Cilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"4062_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u201316.","journal-title":"Lancet Glob Health"},{"key":"4062_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","volume":"9","author":"Y Deng","year":"2022","unstructured":"Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022;9:62\u201379.","journal-title":"Genes Dis"},{"key":"4062_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris 3rd","year":"2013","unstructured":"Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, et al. Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844\u201351.","journal-title":"Ophthalmology"},{"key":"4062_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1167\/iovs.07-1132","volume":"49","author":"KG Csaky","year":"2008","unstructured":"Csaky KG, Richman EA, Ferris FL. 3rd: Report from the NEI\/FDA ophthalmic clinical trial design and endpoints symposium. Invest Ophthalmol Vis Sci. 2008;49:479\u201389.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4062_CR5","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","volume":"114","author":"RW Beck","year":"2007","unstructured":"Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804\u20139.","journal-title":"Ophthalmology"},{"key":"4062_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2022.101160","volume":"97","author":"L Schmetterer","year":"2023","unstructured":"Schmetterer L, Scholl H, Garh\u00f6fer G, Janeschitz-Kriegl L, Corvi F, Sadda SR, et al. Endpoints for clinical trials in ophthalmology. Prog Retin Eye Res. 2023;97:101160.","journal-title":"Prog Retin Eye Res"},{"key":"4062_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jamaophthalmol.2020.1376","volume":"138","author":"SM Waldstein","year":"2020","unstructured":"Waldstein SM, Vogl WD, Bogunovic H, Sadeghipour A, Riedl S, Schmidt-Erfurth U. Characterization of drusen and hyperreflective foci as biomarkers for disease progression in age-related macular degeneration using artificial intelligence in optical coherence tomography. JAMA Ophthalmol. 2020;138:740\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"4062_CR8","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1007\/s40123-023-00807-9","volume":"12","author":"EM Lad","year":"2023","unstructured":"Lad EM, Finger RP, Guymer R. Biomarkers for the progression of intermediate age-related macular degeneration. Ophthalmol Ther. 2023;12:2917\u201341.","journal-title":"Ophthalmol Ther"},{"key":"4062_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology. 2018;125:537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.028.","journal-title":"Ophthalmology"},{"key":"4062_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.101017","volume":"88","author":"Z Wu","year":"2022","unstructured":"Wu Z, Fletcher EL, Kumar H, Greferath U, Guymer RH. Reticular pseudodrusen: a critical phenotype in age-related macular degeneration. Prog Retin Eye Res. 2022;88:101017.","journal-title":"Prog Retin Eye Res"},{"key":"4062_CR11","doi-asserted-by":"publisher","unstructured":"Lydersen S, Skovlund E. Do not adjust for the baseline value in observational studies. Tidsskr Nor Laegeforen. 2021;141. English, Norwegian. https:\/\/doi.org\/10.4045\/tidsskr.21.0657.","DOI":"10.4045\/tidsskr.21.0657"},{"key":"4062_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jamaophthalmol.2022.2113","volume":"140","author":"HMP Dunbar","year":"2022","unstructured":"Dunbar HMP, Behning C, Abdirahman A, Higgins BE, Binns AM, Terheyden JH, et al. MACUSTAR Consortium. Repeatability and discriminatory power of chart-based visual function tests in individuals with age-related macular degeneration: a MACUSTAR Study Report. JAMA Ophthalmol. 2022;140:780\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"4062_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.oret.2019.06.001","volume":"4","author":"TD Keenan","year":"2020","unstructured":"Keenan TD, Vitale S, Agr\u00f3n E, Domalpally A, Antoszyk AN, Elman MJ, et al. Age-Related Eye Disease Study 2 Research Group. Visual acuity outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: age-related eye disease study 2 report number 19. Ophthalmol Retin. 2020;4:3\u201312. https:\/\/doi.org\/10.1016\/j.oret.2019.06.001.","journal-title":"Ophthalmol Retin"},{"key":"4062_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","volume":"121","author":"Z Yehoshua","year":"2014","unstructured":"Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM, Moshfeghi AA, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121:693\u2013701. https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.044.","journal-title":"Ophthalmology"},{"key":"4062_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0161-6420(90)32619-2","volume":"97","author":"D Pauleikhoff","year":"1990","unstructured":"Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch\u2019s membrane: a histochemical and morphological study. Ophthalmology. 1990;97:171\u20138.","journal-title":"Ophthalmology"},{"key":"4062_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/iovs.65.3.4","volume":"65","author":"CA Curcio","year":"2024","unstructured":"Curcio CA, Kar D, Owsley C, Sloan KR, Ach T. Age-related macular degeneration, a mathematically tractable disease. Invest Ophthalmol Vis Sci. 2024;65:4.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4062_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.oret.2017.10.003","volume":"2","author":"GS Ying","year":"2018","unstructured":"Ying GS, Maguire MG, Pan W, Grunwald JE, Daniel E, Jaffe GJ, et al. CATT Research Group. Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials. Ophthalmol Retin. 2018;2:525\u201330. https:\/\/doi.org\/10.1016\/j.oret.2017.10.003.","journal-title":"Ophthalmol Retin"},{"key":"4062_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41433-021-01488-z","volume":"36","author":"MK Grewal","year":"2022","unstructured":"Grewal MK, Chandra S, Gurudas S, Rasheed R, Sen P, Menon D, et al. Functional clinical endpoints and their correlations in eyes with AMD with and without subretinal drusenoid deposits-a pilot study. Eye. 2022;36:398\u2013406.","journal-title":"Eye"},{"key":"4062_CR19","doi-asserted-by":"crossref","unstructured":"Santamar\u00eda J, Pagani F, Mon\u00e9s J. Complete retinal pigment epithelium and outer retinal atrophy: is it really an end-stage atrophy? Eur J Ophthalmol. 2025;35:NP41\u2013NP45.","DOI":"10.1177\/11206721241290263"},{"key":"4062_CR20","first-page":"311","volume":"107","author":"PK Kaiser","year":"2009","unstructured":"Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc. 2009;107:311\u201324.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"4062_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40123-022-00583-y","volume":"12","author":"T Leng","year":"2023","unstructured":"Leng T, Schwartz J, Nimke D, Gallivan M, Fevrier H, Rozario N, et al. Dry age-related macular degeneration: distribution of visual acuity and progression risk in a large registry. Ophthalmol Ther. 2023;12:325\u201340.","journal-title":"Ophthalmol Ther"},{"key":"4062_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100173","volume":"2","author":"EM Lad","year":"2022","unstructured":"Lad EM, Fang V, Tessier M, Rautanen A, Gayan J, Stinnett SS, et al. Longitudinal evaluation of visual function impairments in early and intermediate age-related macular degeneration participants. Ophthalmol Sci. 2022;2:100173.","journal-title":"Ophthalmol Sci"},{"key":"4062_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/OPX.0000000000001624","volume":"98","author":"ME Schneck","year":"2021","unstructured":"Schneck ME, Lott LA, Haegerstrom-Portnoy G, Hewlett S, Gauer BM, Zaidi A. Visual function in eyes with intermediate AMD with and without retinal pigment abnormalities. Optom Vis Sci. 2021;98:64\u201372.","journal-title":"Optom Vis Sci"},{"key":"4062_CR24","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1001\/archopht.123.11.1484","volume":"123","author":"MD Davis","year":"2005","unstructured":"Davis MD, Gangnon RE, Lee LY, Hubbard LD, Klein BEK, Klein R, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol. 2005;123:1484\u201398.","journal-title":"Arch Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04062-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:39:28Z","timestamp":1764599968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04062-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":24,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4062"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04062-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6247988\/v1","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}